| In Focus |
spotlight on the november 13 issue.
- Gross, Robert, MD, PhD, Editor-in-Chief, Neurology. Pages: 2013
|
| Editorial |
blood pressure variability in subacute ischemic stroke: a neglected potential therapeutic target.
- Tsivgoulis, Georgios, MD, FESO, Ntaios, George. Pages: 2014-2015
|
focal cortical thinning is caused by remote subcortical infarcts: spooky action at a distance.
- Smith, Eric, MD, MPH, Arboix, Adria, MD, PhD. Pages: 2016-2017
|
| Article |
effect of blood pressure on 3-month functional outcome in the subacute stage of ischemic stroke.
- Kang, Jihoon, Ko, Youngchai, Park, Jung, Kim, Wook-Joo, Suk Jang, Myung, Yang, Mi, Lee, JiSung, Lee, Juneyoung, Han, Moon-Ku, MD, PhD, Gorelick, Philip, MD, MPH, Bae, Hee-Joon, MD, PhD. Pages: 2018-2024
>
Show/Hide Abstract
Objective: We aimed to study various measures of blood pressure (BP) in the subacute phase of ischemic stroke to determine whether any of them predicted clinical outcome.Methods: In this retrospective observational study, a consecutive series of patients hospitalized for ischemic stroke within 48 hours of onset were enrolled. The subacute stage of stroke was defined as the time period from 72 hours of symptom onset to discharge or transfer. During this period, mean, maximum, maximum - minimum, SD, and coefficient of variation of systolic BP (SBP) and diastolic BP (DBP) were determined. A baseline severity-adjusted analysis was performed using each patient's 3-month modified Rankin Scale score as the primary outcome.Results: Among a total of 2,271 patients, the median number of BP measurements was 34 per person and the median interval from onset to discharge was 8.7 days. Measures of variability of BP were associated with poor outcome. One SD increase of maximum - minimum (odds ratio [OR], 1.26; 95% confidence interval [CI], 1.12-1.42), SD (OR, 1.20; 95% CI, 1.07-1.34), or coefficient of variation (OR, 1.21; 95% CI, 1.09-1.35) for SBP, but not mean level of SBP (OR, 0.92; 95% CI, 0.79-1.07), was independently associated with poor outcome. Results were similar for DBP.Conclusion: This study shows that variability of BP, but not average BP in the subacute stage of ischemic stroke, is associated with functional outcome at 3 months after stroke onset.(C)2012 American Academy of Neurology
|
incident subcortical infarcts induce focal thinning in connected cortical regions.
- Duering, Marco, Righart, Ruthger, Csanadi, Endy, Jouvent, Eric, MD, PhD, Herve, Dominique, Chabriat, Hugues, MD, PhD, Dichgans, Martin. Pages: 2025-2028
>
Show/Hide Abstract
Objective: Brain atrophy is common in subcortical ischemic vascular disease, but the underlying mechanisms are poorly understood. We set out to examine the effects of incident subcortical infarcts on cortical morphology.Methods: A total of 276 subjects with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, an inherited small vessel disease, were enrolled in a prospective study. Incident subcortical infarcts were identified on follow-up magnetic resonance scans after 18, 36, and 54 months using difference images. Probabilistic fiber tracking and cortical thickness measurements were applied to study the longitudinal relationship between incident infarcts and connected cortical areas. Cortical thickness was assessed before and after infarction using FreeSurfer software. Focal cortical thinning was defined as change of cortical thickness in the connected region of interest exceeding the global change of cortical thickness.Results: Nine subjects had a single incident infarct during the follow-up and were suitable for analysis. There was a strong correlation between the probability of connectivity and mean focal cortical thinning (p = 0.0039). In all subjects, there was focal cortical thinning in cortical regions with high probability of connectivity with the incident infarct. This pattern was not observed when using control tractography seeds.Conclusions: Our findings provide in vivo evidence for secondary cortical neurodegeneration after subcortical ischemia as a mechanism for brain atrophy in cerebrovascular disease.(C)2012 American Academy of Neurology
|
cerebral small-vessel disease and progression of brain atrophy: the smart-mr study.
- Kloppenborg, R.P., Nederkoorn, P.J., MD, PhD, Grool, A.M., Vincken, K.L., Mali, W.P.T.M., MD, PhD, Vermeulen, M., MD, PhD, van der Graaf, Y., MD, PhD, Geerlings, M.I.. Pages: 2029-2036
>
Show/Hide Abstract
Objectives: To investigate whether severity and progression of periventricular and deep white matter lesions (WML) and lacunar infarcts were associated with progression of brain atrophy.Methods: Within the SMART-MR study, a prospective cohort on MRI changes in patients with symptomatic atherosclerotic disease, 565 patients (57 +/- 9 years) without large infarcts had vascular screening and 1.5 T MRI at baseline and after a mean follow-up of 3.9 years. With automated brain segmentation, total brain, cortical gray matter, ventricular, and WML volumes were estimated and expressed relative to intracranial volume (%). Lacunar infarcts were rated manually.Results: Using linear regression analyses adjusted for demographics and vascular risk factors, periventricular WML volume at baseline was associated with greater decrease in cortical gray matter volume (B = -1.73%, 95% confidence interval [CI] -3.15% to -0.30%, per 1% WML volume increase) and greater increase in ventricular volume (B = 0.12%, 95% CI 0.04% to 0.20%). Progression of periventricular WML volume corresponded with a greater decrease in cortical gray matter volume (B = -0.45%, 95% CI -0.9% to 0%) and greater increase in ventricular volume (B = 0.15%, 95% CI 0.1% to 0.2%). Presence of lacunar infarcts was associated with greater decline in total brain volume (B = -0.25%, 95% CI -0.49% to -0.01%) and progression of lacunar infarcts with a greater decrease of total brain (B = -0.30%, 95% CI -0.59% to 0.01%) and cortical gray matter volume (B = -0.81%, 95% CI -1.43% to -0.20%).Conclusions: In patients with symptomatic atherosclerotic disease, presence and progression of periventricular WML and lacunar infarcts is associated with greater progression of brain atrophy independent of vascular risk factors.(C)2012 American Academy of Neurology
|
adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes.
- Perreault, Sylvie, BPharm, PhD, Yu, Amy, Cote, Robert, MD, FRCPC, Dragomir, Alice, White-Guay, Brian, MD, FRCPC, Dumas, Stephanie. Pages: 2037-2043
>
Show/Hide Abstract
Objective: To evaluate the relationship between antihypertensive (AH) drug adherence and cardiovascular (CV) outcomes among patients with a recent ischemic stroke and assess the validity of our approach.Methods: A cohort of 14,227 patients diagnosed with an ischemic stroke was assembled from individuals 65 years and older who were treated with AH agents from 1999 to 2007 in Quebec, Canada. A nested case-control design was used to evaluate the occurrence of nonfatal major CV outcomes and mortality. Each case was matched to 15 controls by age and cohort entry time. Medication possession ratio was used for AH agent adherence level. Adjusted conditional logistic regression models were used to estimate the rate ratio of CV events. The validity of the approach was assessed by evaluating the adherence level of CV-protective and non-CV-protective drugs.Results: Mean age was 75 years, 54% were male, 38% had coronary artery disease, 23% had diabetes, 47% dyslipidemia, and 14% atrial fibrillation or flutter. High adherence to AH therapy was mirrored by similar adherence to statins and antiplatelet agents and was associated with a lower risk of nonfatal vascular events compared with lower adherence (rate ratio 0.77 [0.70-0.86]). We observed a paradoxic link between adherence to several drugs and all-cause mortality.Conclusion: Adherence to AH agents is associated with adherence to other secondary preventive therapies and a risk reduction for nonfatal vascular events after an ischemic stroke. Overestimation of all-cause mortality reduction may be related to frailty and comorbidities, which may confound the apparent benefit of different drugs.(C)2012 American Academy of Neurology
|
migraine headache is present in the aura phase: a prospective study.
- Hansen, Jakob, MD, PhD, Lipton, Richard, Dodick, David, Silberstein, Stephen, MD, PhD, Saper, Joel, Aurora, Sheena, Goadsby, Peter, MD, PhD, Charles, Andrew. Pages: 2044-2049
>
Show/Hide Abstract
Objectives: Migraine aura is commonly considered to be a distinct phase of a migraine attack that precedes headache. The objective of the study was to examine a large number of prospectively recorded attacks of migraine with aura and determine the timing of headache and other migraine symptoms relative to aura.Methods: As part of a clinical trial we collected prospective data on the time course of headache and other symptoms relative to the aura. Patients (n = 267) were enrolled from 16 centers, and asked to keep a headache diary for 1 month (phase I). They were asked to record headache symptoms as soon as possible after aura began and always within 1 hour of aura onset. A total of 456 attacks were reported during phase I by 201 patients. These patients were then randomized and included in phase II, during which a total of 405 attacks were reported in 164 patients. In total, we present data from 861 attacks of migraine with aura from 201 patients.Results: During the aura phase, the majority of attacks (73%) were associated with headache. Other migraine symptoms were also frequently reported during the aura: nausea (51%), photophobia (88%), and photophobia (73%). During the first 15 minutes within the onset of aura, 54% of patients reported headache fulfilling the criteria for migraine.Conclusion: Our results indicate that headaches as well as associated migraine symptoms are present early, during the aura phase of the migraine attack in the majority of patients.(C)2012 American Academy of Neurology
|
dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3.
- Wadman, Renske, Vrancken, Alexander, MD, PhD, van den Berg, Leonard, MD, PhD, Ludo van der Pol, W., MD, PhD. Pages: 2050-2055
>
Show/Hide Abstract
Objective: Spinal muscular atrophy (SMA) is pathologically characterized by degeneration of anterior horn cells. Recent observations in animal models of SMA and muscle tissue from patients with SMA suggest additional abnormalities in the development and maturation of the neuromuscular junction. We therefore evaluated neuromuscular junction function in SMA with repetitive nerve stimulation.Methods: In this case-control study, repetitive nerve stimulation was performed in 35 patients with SMA types 2, 3, and 4, 20 healthy controls, and 5 controls with motor neuron disease.Results: Pathologic decremental responses (>10%) during 3-Hz repetitive nerve stimulation were observed in 17 of 35 patients (49%) with SMA types 2 and 3, but not in healthy controls or controls with motor neuron disease. None of the patients or controls had an abnormal incremental response of >60%. The presence of an abnormal decremental response was not specific for the type of SMA, nor was it associated with compound muscle action potential amplitude, clinical scores, or disease duration. Two of 4 patients with SMA type 3 who tried pyridostigmine reported increased stamina.Conclusions: These data suggest dysfunction of the neuromuscular junction in patients with SMA types 2 and 3. Therefore, drugs that facilitate neuromuscular transmission are candidate drugs for evaluation in carefully designed, placebo-controlled, clinical trials.(C)2012 American Academy of Neurology
|
video game-based coordinative training improves ataxia in children with degenerative ataxia.
- Ilg, Winfried, Schatton, Cornelia, Schicks, Julia, Giese, Martin, Schols, Ludger, Synofzik, Matthis. Pages: 2056-2060
>
Show/Hide Abstract
Objective: Degenerative ataxias in children present a rare condition where effective treatments are lacking. Intensive coordinative training based on physiotherapeutic exercises improves degenerative ataxia in adults, but such exercises have drawbacks for children, often including a lack of motivation for high-frequent physiotherapy. Recently developed whole-body controlled video game technology might present a novel treatment strategy for highly interactive and motivational coordinative training for children with degenerative ataxias.Methods: We examined the effectiveness of an 8-week coordinative training for 10 children with progressive spinocerebellar ataxia. Training was based on 3 Microsoft Xbox Kinect video games particularly suitable to exercise whole-body coordination and dynamic balance. Training was started with a laboratory-based 2-week training phase and followed by 6 weeks training in children's home environment. Rater-blinded assessments were performed 2 weeks before laboratory-based training, immediately prior to and after the laboratory-based training period, as well as after home training. These assessments allowed for an intraindividual control design, where performance changes with and without training were compared.Results: Ataxia symptoms were significantly reduced (decrease in Scale for the Assessment and Rating of Ataxia score, p = 0.0078) and balance capacities improved (dynamic gait index, p = 0.04) after intervention. Quantitative movement analysis revealed improvements in gait (lateral sway: p = 0.01; step length variability: p = 0.01) and in goal-directed leg placement (p = 0.03).Conclusions: Despite progressive cerebellar degeneration, children are able to improve motor performance by intensive coordination training. Directed training of whole-body controlled video games might present a highly motivational, cost-efficient, and home-based rehabilitation strategy to train dynamic balance and interaction with dynamic environments in a large variety of young-onset neurologic conditions.Classification of evidence: This study provides Class III evidence that directed training with Xbox Kinect video games can improve several signs of ataxia in adolescents with progressive ataxia as measured by SARA score, Dynamic Gait Index, and Activity-specific Balance Confidence Scale at 8 weeks of training.(C)2012 American Academy of Neurology
|
traumatic brain injury, paraquat exposure, and their relationship to parkinson disease.
- Lee, Pei-Chen, Bordelon, Yvette, MD, PhD, Bronstein, Jeff, MD, PhD, Ritz, Beate, MD, PhD. Pages: 2061-2066
>
Show/Hide Abstract
Objectives: Traumatic brain injury (TBI) increased risk of Parkinson disease (PD) in many but not all epidemiologic studies, giving rise to speculations about modifying factors. A recent animal study suggested that the combination of TBI with subthreshold paraquat exposure increases dopaminergic neurodegeneration. The objective of our study was to investigate PD risk due to both TBI and paraquat exposure in humans.Methods: From 2001 to 2011, we enrolled 357 incident idiopathic PD cases and 754 population controls in central California. Study participants were asked to report all head injuries with loss of consciousness for >5 minutes. Paraquat exposure was assessed via a validated geographic information system (GIS) based on records of pesticide applications to agricultural crops in California since 1974. This GIS tool assesses ambient pesticide exposure within 500 m of residences and workplaces.Results: In logistic regression analyses, we observed a 2-fold increase in risk of PD for subjects who reported a TBI (adjusted odds ratio [AOR] 2.00, 95% confidence interval [CI] 1.28-3.14) and a weaker association for paraquat exposures (AOR 1.36, 95% CI 1.02-1.81). However, the risk of developing PD was 3-fold higher (AOR 3.01, 95% CI 1.51-6.01) in study participants with a TBI and exposure to paraquat than those exposed to neither risk factor.Conclusions: While TBI and paraquat exposure each increase the risk of PD moderately, exposure to both factors almost tripled PD risk. These environmental factors seem to act together to increase PD risk in a more than additive manner.(C)2012 American Academy of Neurology
|
| Views & Reviews |
parkinson disease and driving: an evidence-based review.
- Crizzle, Alexander, PhD, MPH, Classen, Sherrilene, PhD, MPH, Uc, Ergun. Pages: 2067-2074
>
Show/Hide Abstract
The growing literature on driving in Parkinson disease (PD) has shown that driving is impaired in PD compared to healthy comparison drivers. PD is a complex neurodegenerative disorder leading to motor, cognitive, and visual impairments, all of which can affect fitness to drive. In this review, we examined studies of driving performance (on-road tests and simulators) in PD for outcome measures and their predictors. We searched through various databases and found 25 (of 99) primary studies, all published in English. Using the American Academy of Neurology criteria, a study class of evidence was assigned (I-IV, I indicating the highest level of evidence) and recommendations were made (Level A: predictive or not; B: probably predictive or not; C: possibly predictive or not; U: no recommendations). From available Class II and III studies, we identified various cognitive, visual, and motor measures that met different levels of evidence (usually Level B or C) with respect to predicting on-road and simulated driving performance. Class I studies reporting Level A recommendations for definitive predictors of driving performance in drivers with PD are needed by policy makers and clinicians to develop evidence-based guidelines.(C)2012 American Academy of Neurology
|
| Clinical/Scientific Notes |
pml-iris in a patient treated with brentuximab.
- von Geldern, Gloria, Pardo, Carlos, Calabresi, Peter, Newsome, Scott. Pages: 2075-2077
|
a 66-year-old patient with vanishing white matter disease due to the p.ala87val eif2b3 mutation.
- Ghezzi, Laura, Scarpini, Elio, Rango, Mario, Arighi, Andrea, Bassi, Maria, Tenderini, Erika, De Riz, Milena, Jacini, Francesca, Fumagalli, Giorgio, Pietroboni, Anna, Galimberti, Daniela, Bresolin, Nereo. Pages: 2077-2078
|
| Reflections: Neurology and the Humanities |
a neurologist, an emr, and a patient.
- Marie Llaneza Ramos, Vesper. Pages: 2079-2080
|
| NeuroImages |
contrast-enhanced ultrasound and detection of carotid plaque neovascularization.
- Kunte, Hagen, Schmidt, Charlotte, Harms, Lutz, Ruckert, Ralph-Ingo, MD, PhD, Grigoryev, Maria, Fischer, Thomas. Pages: 2081
|
| Resident &Fellow Section |
emerging subspecialties in neurology: neuroimmunology.
- Clardy, Stacey, MD, PhD. Pages: e178-e180
|
teaching neuroimages: a case of tubercular arteritis and stroke after early discontinuation of antibiotic therapy.
- Parish, Leslie, Pirisi, Angelo. Pages: e181
|
teaching neuroimages: crossed cerebellar diaschisis in hemispheric status epilepticus.
- Massaro, Allie. Pages: e182
|
| DEPARTMENT: PDF Only |
in the next issue of neurology(r).
(PDF Only) Pages: C3
|